Evidence map›Paper›PMID 41636491›Full record

ArticleAntimicrobial agents and chemotherapy2026

Ceftazidime/avibactam and aztreonam combined with an aminoglycoside combat metallo-β-lactamase-producing

Arunkumar Karunanidhi, Nidhi Singh, Jackson V Watkins, Nicholas M Smith, Yanan Zang, Xindi Shan, Gilberto Espinoza, Jian Li, Yinzhi Lang, Jürgen B Bulitta and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Arunkumar KarunanidhiDepartment of Pharmacy Practice, University of Illinois Chicago Retzky College of Pharmacy, Chicago, Illinois, USA.
Nidhi SinghDepartment of Pharmacy Practice, University of Illinois Chicago Retzky College of Pharmacy, Chicago, Illinois, USA.
Jackson V WatkinsDepartment of Pharmacy Practice, University of Illinois Chicago Retzky College of Pharmacy, Chicago, Illinois, USA.
Nicholas M SmithDepartment of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, New York, USA.ORCID 0000-0002-0212-2787
Yanan ZangDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA.
Xindi ShanDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA.
Gilberto EspinozaDepartment of Pharmacy Practice, University of Illinois Chicago Retzky College of Pharmacy, Chicago, Illinois, USA.
Jian LiDepartment of Microbiology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.ORCID 0000-0001-7953-8230
Yinzhi LangDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA.
Jürgen B BulittaDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA.
Zackery P BulmanDepartment of Pharmacy Practice, University of Illinois Chicago Retzky College of Pharmacy, Chicago, Illinois, USA.ORCID 0000-0002-5396-911X

Funding

Precise Combination Strategies Targeting Carbapenem-Resistant Klebsiella pneumoniaeR01AI173064 · NIAID · UNIVERSITY OF ILLINOIS AT CHICAGO · PI Zackery P. Bulman · 2023 to 2026
$3.0M
National Institute of Allergy And Infectious Diseases of the National Institutes of Health R01AI173064NIAID NIH HHS R01 AI173064
6 · The paper itself

Abstract

There is an urgent need for additional therapeutic solutions to treat serious bacterial infections caused by metallo-β-lactamase (MBL)-producing

Indexed as

AminoglycosidesAnti-Bacterial AgentsAzabicyclo CompoundsAztreonambeta-LactamasesCeftazidimeKlebsiella pneumoniaeDrug CombinationsDrug SynergismHumansKlebsiella InfectionsMicrobial Sensitivity TestsThird Generation CephalosporinsAminoglycosidesAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsAztreonambeta-LactamasesCeftazidimeDrug CombinationsThird Generation Cephalosporinsamikacinaztreonamceftazidime/avibactamcombinationshollow fiber infection modelKlebsiella pneumoniaemetallo-β-lactamaseplazomicin

Identifiers

PMID41636491
PMCPMC12959111

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.